

University of Dundee

## Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis

Gao, Yong-Hua; Abo Leyah, Hani; Finch, Simon; Lonergan, Mike; Aliberti, Stefano; De Soyza, Anthony

*Published in:*  
American Journal of Respiratory and Critical Care Medicine

*DOI:*  
[10.1164/rccm.201910-1972OC](https://doi.org/10.1164/rccm.201910-1972OC)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Gao, Y-H., Abo Leyah, H., Finch, S., Lonergan, M., Aliberti, S., De Soyza, A., Fardon, T. C., Tino, G., & Chalmers, J. D. (2020). Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. *American Journal of Respiratory and Critical Care Medicine*, 201(12), 1499-1507. <https://doi.org/10.1164/rccm.201910-1972OC>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# **The Relationship Between Symptoms, Exacerbations and Treatment Response in Bronchiectasis**

**Yong-hua Gao<sup>1,2</sup>, Hani Abo Leyah<sup>2</sup>, Simon Finch<sup>2</sup>, Mike Lonergan<sup>2</sup>, Stefano Aliberti<sup>3</sup>, Anthony De Soyza<sup>4</sup>, Thomas C Fardon<sup>2</sup>, Gregory Tino<sup>5</sup>, James D Chalmers<sup>2</sup>**

<sup>1</sup>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

<sup>2</sup>Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom

<sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

<sup>4</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

<sup>5</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

**Corresponding author:** Prof James D Chalmers, Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. E-mail: [jchalmers@dundee.ac.uk](mailto:jchalmers@dundee.ac.uk)

**Running head:** Symptom and exacerbation in bronchiectasis

**Subject category:** 10.16: Non-cystic fibrosis bronchiectasis

**Word count of the manuscript:** 3726

**Supported by:** This study was funded by the European Respiratory Society through the EMBARC2 consortium and an ERS long-term research Fellowship 2019 to YHG

(LTRF201901-00561). JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research.

Author contributions:

Conception and design: YHG, HAL, JDC

Patient recruitment and data collection: HAL, SF, TCF, GT, JDC

Analysis and interpretation: YHG, ML, SA, ADS, JDC

Drafting the manuscript: YHG, JDC

Revising the manuscript and final approval: all authors

This article has an online data supplement, which is accessible from this issue's table of content online at [www.atsjournals.org](http://www.atsjournals.org)

### **At a Glance Commentary**

#### **Scientific knowledge on the subject:**

Guidelines currently consider the prevention of exacerbations and reducing daily symptoms as separate objectives. The “threshold” concept of exacerbations suggests that patients report exacerbations when daily symptoms exceed normal day to day variation, and daily symptoms pass a threshold of severity above which patients feel the need to take antibiotics. Therefore, it is reasonable to hypothesize that patients with a higher daily symptom burden may experience more exacerbations. Accordingly, improving daily symptoms should reduce exacerbations, particularly in individuals with high symptom burden.

**What this study added to the field:**

This is the first study to demonstrate that a high daily respiratory symptom burden, measured using the St Georges Respiratory Questionnaire, is associated with increased exacerbation risk and shorter time to first exacerbation in bronchiectasis. In a post-hoc analysis of a randomized trial, patients with higher daily symptom burdens had increased time to first exacerbation, fewer exacerbations, symptom improvements and a trend for reduced exacerbation rates when treated with inhaled mannitol compared with control. This highlights the importance of therapies focused on symptom improvements in preventing exacerbation and the potential need for multimodality treatment in patients with the most severe disease.

## Abstract

**Rationale:** Bronchiectasis guidelines regard treatment to prevent exacerbation and treatment of daily symptoms as separate objectives.

**Objective:** We hypothesized that patients with greater symptoms would be at higher risk of exacerbations and therefore a treatment aimed at reducing daily symptoms would also reduce exacerbations in highly symptomatic patients.

**Methods:** An observational cohort of 333 patients from the East of Scotland (2012-2016). Symptoms were either modelled as a continuous variable or patients were classified as high, moderate and low symptom burden (>70, 40-70 and <40 using the SGRQ symptom score). The hypothesis that exacerbation reductions would only be evident in highly symptomatic patients was tested in a post-hoc analysis of a randomized trial of inhaled dry powder mannitol (N=461 patients)

**Measurement and Main Results:** In the observational cohort daily symptoms were a significant predictor of future exacerbations (rate ratio [RR] 1.10, 95% confidence interval [CI] 1.03-1.17, P=0.005). Patients with higher symptom scores had higher exacerbation rates (RR 1.74, 95% CI 1.12-2.72, P=0.01) over 12 months follow-up compared to those with lower symptoms. Inhaled mannitol treatment improved the time to first exacerbation (hazard ratio [HR] 0.56; 95% CI 0.40-0.77; P<0.001) and the proportion of patients remaining exacerbation free for 12 months treatment was higher in the mannitol group (32.7% vs. 14.6%; RR 2.84, 95% CI 1.40-5.76; P=0.003) but only in highly symptomatic patients. In

contrast no benefit was evident in patients with lower symptom burden.

**Conclusions:** Highly symptomatic patients have increased risk of exacerbations, and exacerbation benefit with inhaled mannitol was only evident in patients with high symptom burden.

## Introduction

Exacerbations of bronchiectasis are acute events characterized by a worsening of daily symptoms usually requiring antibiotic treatment (1, 2). Exacerbations are a major driver of disease progression and are associated with poor prognosis and high healthcare costs (3–5). Preventing exacerbations are one of key goals in international guidelines for bronchiectasis. Macrolides and inhaled antibiotics are recommended as the first-line treatment for patients with three or more exacerbations per year (after underlying causes have been treated and airway clearance has been optimized) (6, 7).

The published guidelines consider the prevention of exacerbations and reducing daily symptoms as separate objectives (6–8). This is consistent with recent evidence showing that prophylactic antibiotic treatments, in particular, reduce exacerbations without a major impact on daily symptoms (9, 10). A recent meta-analysis found that inhaled antibiotics reduce exacerbation frequency (11), but have no significant impact on daily symptoms. Even larger reductions in exacerbation rates were observed for macrolides, again without clinically meaningful improvements in symptoms (12). Notably macrolides appear to be effective at reducing exacerbations regardless of the severity of baseline symptoms (12).

The current definition of exacerbation in bronchiectasis is based on an increase in respiratory symptoms such as cough, sputum and breathlessness, requiring antibiotic treatment (2). It is reasonable to hypothesize that patients with more severe daily symptoms would require smaller incremental changes to pass a threshold prompting treatment and would therefore be more likely to report exacerbations. (13). Accordingly

improving daily symptoms should reduce exacerbations. In chronic obstructive pulmonary disease (COPD), several studies have suggested that highly symptomatic patients are more likely to have exacerbations. Highly symptomatic COPD patients have clearer reductions in exacerbations from bronchodilators than those with low daily symptoms (14, 15). In contrast inhaled corticosteroids reduce exacerbations of COPD independent of daily symptoms (16). Such a paradigm is not established in bronchiectasis. No previous study has investigated the relationship between respiratory symptoms and exacerbations, or investigated whether a higher daily symptom burden could identify bronchiectasis patient population more likely to have exacerbation benefit with a symptom targeting therapy (6, 7).

The dominant symptoms of bronchiectasis are cough and sputum production. For this reason, bronchiectasis guidelines recommend airway clearance with or without mucoactive drugs as key strategies to reduce symptoms (6-8). The largest study to evaluate a mucoactive drug in bronchiectasis found that inhaled dry powder mannitol did not reduce exacerbation frequency despite achieving a statistically significant improvement in daily symptoms measured using the SGRQ (17). We have tested the relationship between baseline symptoms and exacerbations in an observational cohort study and re-analysed the prior randomized controlled trial of inhaled dry powder mannitol (17). We now show that highly symptomatic patients are at greater risk of exacerbations and that mannitol achieved a reduction in exacerbations in the subgroup of patients with a high symptom burden at baseline.



## Methods

### Study Design

#### Observational cohort

This was a prospective observational study (TAYBRIDGE [Tayside Bronchiectasis Registry Integrating Datasets, Genomics, and Enrolment into Clinical Trials] registry) at two hospitals in the East of Scotland 2012–2016. The study was approved by the East of Scotland Research Ethics committee (12/ES/0059), and all patients gave written informed consent. Inclusion criteria were age >18 years, high-resolution computed tomography–confirmed bronchiectasis, and clinical symptoms consistent with bronchiectasis. Exclusion criteria were inability to give informed consent, active nontuberculous mycobacterial infection, active allergic bronchopulmonary aspergillosis, active tuberculosis, active malignancy, cystic fibrosis, or pulmonary fibrosis with secondary traction bronchiectasis.

Daily symptom burden was measured using SGRQ symptom score. The SGRQ is an instrument that is validated in bronchiectasis and has been extensively used in bronchiectasis trials (9, 18, 19). We divided patients with 3 groups: high symptom burden (>70), moderate symptom burden (40–70), and low symptom burden (<40). These cut-offs were determined a priori based on tertiles (tertiles were identified at cut-offs of 47 and 72 points. Therefore, for clinical ease, 40 and 70 were chosen as cut-offs). A sensitivity analysis was performed using the SGRQ total score.

Severity of disease was evaluated using the bronchiectasis severity index (BSI), as previously

described (1). Exacerbations were recorded by patient self-report and further validated by reviewing prescription records for antibiotics which are available through electronic medical records for all participants. The primary outcome was the relationship between daily symptoms and exacerbations over 12 months after baseline. The Secondary outcome was time to first exacerbation.

### **Mannitol study**

We conducted a post hoc analysis of a randomized double-blind controlled trial of inhaled dry powder mannitol treatment in bronchiectasis. Results of the original trial have been published (17). Patients were randomized (1:1) to 52 weeks treatment with inhaled mannitol 400 mg or low-dose mannitol control twice a day. Patients were included if they had HRCT confirmed bronchiectasis, baseline FEV<sub>1</sub> ≥ 40% and ≤ 85% predicted and ≥ 1 L, a baseline SGRQ score ≥ 30 and at least 2 exacerbations in the previous year or 4 exacerbations in the previous 2 years.

The primary end point was exacerbation rates per patient per year, and the secondary end points included time to first exacerbation and quality of life (QoL) measured by change in the SGRQ questionnaire.

Individual participant data from the study was used to firstly confirm the relationship between daily symptoms and exacerbation observed in our prospective observational study and secondly to examine whether baseline SGRQ symptom score would predict treatment response. Treatment response was based on time to first exacerbation, frequency of exacerbations, number of subjects experiencing exacerbations and change in SGRQ total

score from baseline to week 52. Daily symptom scores were analysed as a continuous variable and using the categories according to the cut-off points established in the observational cohort study.

### **Statistical Analysis**

Statistical analysis was performed using the SPSS version 22.0 software (IBM) and R software version 3.6.1. Variables were presented by number (percentage), mean (standard deviation, SD) or median (interquartile range, IQR), as appropriate. We used the Student's t test, ANOVA tests, or their corresponding non-parametrical tests for continuous variables, and chi-square test or Fisher exact test for categorized variables, for the comparisons of groups when required. Patients were stratified by SGRQ symptom score at baseline as high (>70), moderate (40-70), low (<40) symptom burden. The post hoc analyses of mannitol were conducted using the modified intent-to-treat population. Spearman correlation was used to examine the relationship between linear variables.

Unadjusted and adjusted analyses were performed using a negative binomial model to assess the relationship between baseline SGRQ symptom scores and the frequency of exacerbations and hospitalizations. Time to first exacerbation was modelled using Cox's proportional hazards models. The rate ratio (RR), hazard ratio (HR) and corresponding 95% confidence interval (CI) for exacerbations and time to first exacerbation for the uncategorized score represent 10 points increase in SGRQ symptom score when entered as a continuous variable. Relevant clinical factors that could affect the outcomes or baseline SGRQ symptom scores were included in the adjusted analyses: age, sex, body mass index

(BMI), smoking status, FEV<sub>1</sub> % of predicted at baseline, radiological score, bacterial isolation (*Pseudomonas aeruginosa*, *Haemophilus influenzae* and *Moraxella catarrhalis*), idiopathic and post-infective etiologies. To explore the relationship between baseline SGRQ and treatment response generalized additive models were fitted to the data from the study (using the mgcv library within R 3.6.1) with smooth (spline) terms for both control and treatment effects of baseline SGRQ symptom score. The model of exacerbation frequency again used a negative binomial error distribution, and a log link function, while that of time to first exacerbation used a Cox proportional hazard model. A two-tailed P value of less than 0.05 was regarded as statistically significant.

## Results

### Observational Study

Three hundred thirty-three clinically stable patients were recruited for the study. Table 1 shows the demographic characteristics of the study population. Median age (IQR) was 68 (60-74) years old, 63.1% were female and median FEV<sub>1</sub> was 72 (50-90) % of predicted. Most patients were classified as idiopathic (47.7%) and post-infective (18.6%). *P. aeruginosa* was present in the sputum of 13.9% patients at baseline, and median SGRQ symptom score at baseline was 59.8 (40.1-79.8) points. Eighty-two patients (24.6%) had low symptom burden, 127 patients (38.1%) had moderate symptom burden and 124 (37.2%) patients had high symptom burden. Patients with high symptom burden had higher BMI, lower FEV<sub>1</sub>% of predicted, lower LCQ total score, a higher number of exacerbations in the previous year, a higher isolation of *P. aeruginosa*, *H. influenzae* and *M. catarrhalis*, and a lower proportion of

post-infective etiology and stroke. No other differences among groups were found.

SGRQ symptom score was weakly associated with FEV<sub>1</sub> % of predicted ( $r=-0.37$ ;  $P<0.001$ ) and disease severity ( $r=0.39$ ;  $P<0.001$  with BSI score and  $r=0.25$ ;  $P<0.001$  with FACED score) (Figure S1 online). Compared to those with moderate and low symptom burden, patients with high symptom burden had more exacerbations in the previous year, median (3 [1-5] vs. 1.5 [0-2] vs. 1 [0-2],  $P<0.001$ ), lower FEV<sub>1</sub> % of predicted (56.1 [42.2-81.9] vs. 74.0 [59.4-91.8] vs. 82.9 [68.0-96.9],  $P<0.001$ ) and more severe disease using the BSI (10 [6-13] vs. 6 [4-8] vs. 5 [3-7.25],  $P<0.001$ ) (Figure 1).

Symptoms at baseline predicted the risk of exacerbations during follow-up. The median (interquartile range, IQR) exacerbation rate per patient per year in the following year was 2 (0-4), 1 (0-2) and 1 (0-1) in the high, moderate and low symptom group ( $P<0.001$ ), respectively.

The results of univariate and multivariate analyses evaluating the relationship between the SGRQ symptom score and risk of exacerbations, hospitalizations and time to first exacerbation are summarized in Table 2. SGRQ symptom score was a significant predictor of future exacerbations (RR 1.10, 95% CI 1.03-1.17,  $P=0.005$  for a 10 point change in SGRQ symptom score) and hospitalizations (RR 1.19, 95% CI 1.02-1.35,  $P=0.03$ ) when entered as a continuous variable in the negative binomial model and a trend for shorter time to first exacerbation (HR 1.04, 95% CI 0.997-1.10,  $P=0.27$ ) after adjusting for the relevant confounders. Using the cut-offs, high SGRQ symptom score  $>70$  was associated with significantly higher exacerbation risk (RR 2.33; 95% CI 1.61-3.37;  $p<0.001$ ), higher

hospitalization risk (RR 6.88, 95% CI 2.59-17.73,  $P<0.001$ ) and shorter time to first exacerbation (HR 1.41; 95% CI 0.99-2.02;  $p=0.06$ ) compared to patients with lower symptom scores. Compared to those with low symptom scores, a moderate SGRQ symptom score (40-70) was also associated with higher hospitalization risk (RR 3.53, 95% 1.31-9.54,  $P=0.01$ ). Nevertheless, the difference was not statistically significant (RR 1.07; 0.73 to 1.58;  $P=0.72$  for exacerbation rate and HR 0.96; 95% CI 0.66-1.38;  $P=0.30$  for time to first exacerbation; respectively) in unadjusted analysis when comparing moderate and low symptom groups. The higher risk in the highly symptomatic group remained significant even after adjusting the effect of potential confounders for the risk of having bronchiectasis exacerbation (RR 1.74; 95% CI 1.12-2.72;  $p=0.01$ ) and hospitalization (RR 3.28, 95% CI 1.09-9.88,  $P=0.04$ ). However, high SGRQ score categories were not significantly associated with shorter time to first exacerbation compared with the low burden (HR 1.16; 95% CI 0.76-1.77;  $P=0.49$ ) after adjusting the relevant confounders. Notably, the relationship between SGRQ symptom score and exacerbation risk were not influenced by disease severity regardless of whether this was assessed by BSI or  $FEV_1$  % of predicted ( $P_{\text{interaction}}=0.25$  and  $P_{\text{interaction}}=0.62$ , respectively) (Figure S2 online). Repeating these analyses using the SGRQ total score rather than the symptom score produced similar results (Table S1 online). Analysis using the Leicester cough questionnaire also found similar results (Table S2 online).

### **Mannitol Study**

The main clinical characteristics of patients included in the study has been reported previously (Table S3 online). Median age (IQR) was 63 (53-69) years old, 62.7% were female

and median FEV<sub>1</sub> was 61.9 (51.9-72.3) % of predicted. Most patients were classified as idiopathic (38.8%) and post-infective (33.0%). *P. aeruginosa* was present in the sputum of 17.1% patients, and median SGRQ symptom score at baseline was 66.1 (53.9-77.7) points.

SGRQ symptom score was weakly associated with 24 hour sputum weight ( $r=0.09$ ;  $P=0.05$ ) and disease severity ( $r=0.23$ ;  $P<0.001$  with Bronchiectasis Severity Index [BSI] score), but not FEV<sub>1</sub> % of predicted ( $r=-0.06$ ,  $P=0.19$ ), although this analysis is limited by the inclusion criteria which required FEV<sub>1</sub> between 40 and 85% predicted. Thirty-five patients (7.6%) had low symptom burden, 232 patients (50.3%) had moderate symptom burden and 194 (42.1%) patients had high symptom burden using the cut-offs established in the observational cohort. No statistically significant differences among clinical characteristics according to symptom burden were found.

A total of 380 patients with documented baseline SGRQ symptom score (82.4%) completed the double-blind treatment period.

The results of univariate and multivariate analyses evaluating the relationship between the SGRQ score and risk of exacerbations and time to first exacerbation are summarized in Table 3. SGRQ symptom score was a significant predictor of future exacerbations (RR 1.09, 95% CI 1.02-1.17,  $P=0.02$  for each 10 point increment in the score) and higher symptoms were associated with shorter time to first exacerbation (HR 1.09, 95% CI 1.02-1.15,  $P=0.009$ ) after adjusting the relevant confounders. In unadjusted analysis, higher SGRQ symptom score categories were associated with significantly higher exacerbation risk (RR 1.71; 95% CI 1.07-2.76;  $p=0.03$ ), and shorter time to first exacerbation (HR 1.87; 95% CI 1.16-3.02;  $p=0.01$ )

compared with low symptom burden. These relationships remained significant even after adjusting the effect of potential confounders for the risk of having bronchiectasis exacerbation (RR 1.75; 95% CI 1.07-2.86;  $p=0.03$ ), and shorter time to first exacerbation compared with the low burden (HR 1.78; 95% CI 1.09-2.90;  $p=0.02$ ) after adjusting the relevant confounders. We further re-analyzed the data only in the control arm and found that higher symptom burden was still associated with higher exacerbation risk (Table S4 online). We found no modifying effect of disease severity, regardless of whether this was assessed by BSI or FEV<sub>1</sub> % of predicted on the relationship between symptoms and exacerbations ( $P_{\text{interaction}}=0.65$  and  $P_{\text{interaction}}=0.54$ , respectively). Figure S3 (online) shows that patients with higher symptom scores experienced more exacerbations in mild, moderate and severe subgroups based on the BSI.

**Primary endpoint.** In the original trial, Mannitol treatment was not associated with reduced exacerbations compared to the low dose mannitol control with a rate ratio of 0.92 (95% CI 0.78 to 1.08),  $P=0.31$ . We observed a relationship between exacerbation benefit with mannitol compared to control with increasing SGRQ (Figure 2). Comparing inhaled mannitol with control, there was no benefit in exacerbation rate for patients with low symptom burden (RR 1.01; 95% CI 0.41-2.46;  $P=0.98$ ) and moderate symptom burden (RR 1.07; 95% CI 0.78-1.47;  $P=0.69$ ). However, there was a clear trend for exacerbation reduction in favor of inhaled mannitol treatment patients with baseline high symptom burden (RR 0.76; 95% CI 0.54-1.06;  $P=0.107$ ) despite lack of statistical significance. We then determined the proportion of patients who had no exacerbation for 12 months after receiving inhaled mannitol or control. In patients with high symptom burden, we found that



32.7% in inhaled mannitol group had no exacerbation compared with 14.6% in control group (RR 2.84, 95% CI 1.40-5.76,  $P=0.003$ ). However, there was no significant difference in the proportion of patients who had no exacerbations in patients with low or moderate symptom burden (Moderate 26.7% vs. 25.9%, RR 1.05, 95% CI 0.58-1.88,  $P=0.88$ ; Low 52.6% vs. 37.5%; RR 1.85, 95% CI 0.49-7.18;  $P=0.37$ ).

**Secondary endpoint.** For the secondary endpoints of time to first exacerbation, inhaled mannitol treatment prolonged the time to first exacerbation (193 days vs. 118 days; HR 0.56; 95% CI 0.40-0.77;  $P<0.001$ ) compared with control in the high symptom burden group (Figure S4 online). The effect was not different in moderate and low symptom burden groups (HR 0.99; 95% CI 0.73-1.34;  $P=0.94$  and HR 0.76; 95% CI 0.31-1.88;  $P=0.55$ ; respectively) (Figure 3). The relationship between SGRQ and time to first exacerbation in the generalized additive model is shown in figure 2B. Patients with higher symptom burden had a significant improvement in SGRQ total scores above the minimal clinically important difference (MCID) in favor of inhaled mannitol treatment compared with control (mean difference -5.86; 95% CI -10.49 to -1.22;  $P=0.014$ ). However, there was no improvement in SGRQ total score for patients with moderate (mean difference 1.06; 95% CI -3.22 to 5.33;  $P=0.63$ ) and low symptom burden at baseline (mean difference -0.85; 95% CI -10.41 to 8.71;  $P=0.86$ ) on mannitol compared with control. A decrease in SGRQ total score of greater or equal to four points is regard as clinically meaningful. There was no significant difference in the percentage of responders in patients with low or moderate symptom burden. In patients with high symptom burden, 75% achieved a SGRQ total score decrease above the MCID compared with 52.7% of patients in the control group ( $P=0.001$ ). There were no

overall improvements in the FEV<sub>1</sub> % of predicted among groups.

## Discussion

Exacerbations and daily symptoms have the greatest impact on patient's survival and quality of life in bronchiectasis and therefore reducing exacerbations and relieving daily symptoms are the key objectives of therapy. We, for the first time, demonstrate that high respiratory symptom burden, regardless of whether these are measured by SGRQ symptom score, total score or LCQ total score, is associated with increased exacerbation risk and shorter time to first exacerbation in bronchiectasis. This led us to hypothesize that improving daily symptom could reduce exacerbations. We then conducted a post-hoc analysis of one previously published "negative" randomized controlled trial of inhaled mannitol, where we found that only patients with high baseline symptom burden had increased time to first exacerbation, fewer exacerbations, symptom improvements and a trend for reduced exacerbation rates when treated with inhaled mannitol compared with control. These findings suggest that control of daily symptoms can result in reduced exacerbations if targeted towards highly symptomatic patients

Guidelines primarily consider these outcomes separately, with a different algorithm for patients with 3 or more exacerbations per year where prophylactic antibiotic therapies are considered, compared to symptomatic patients with and without exacerbations where bronchitic symptoms are treated with airway clearance with or without mucoactive drugs and breathlessness treated with pulmonary rehabilitation and bronchodilators where appropriate (6, 7).

It is intuitive that, as in other chronic conditions like COPD (20–22), there would be a relationship between daily symptoms and exacerbations but ours is, to the authors knowledge, the first study to specifically address this question. The “threshold” concept of exacerbations suggests that patients report exacerbations when daily symptoms exceed normal day to day variation, and daily symptoms pass a threshold of severity above which patients feel the need to take antibiotics (2, 6, 7). This threshold may be different from patient to patient. Some exacerbation events may involve a very large increase in symptoms while others may represent only small changes from the patient’s usual baseline. If this concept is true, patients with a higher baseline level of symptoms would be closer to the threshold and would therefore require a lesser insult to report exacerbations, resulting in a higher frequency of events. This model also predicts that reducing daily symptoms would therefore result in reduced exacerbation frequency.

It is puzzling therefore that our recent meta-analysis of macrolides found no impact of baseline symptoms on the benefit of macrolides vs placebo for reducing exacerbations (12). Patients with an SGRQ score >50 points had a rate ratio of 0.5 (0.28-0.90) for exacerbation frequency which was the same as for the patients with SGRQ scores <30 (0.50 95% CI 0.29-0.84). The 50% reduction in exacerbations was accompanied by only a borderline improvement in symptoms. Likewise, in the ORBIT studies of inhaled liposomal ciprofloxacin there was a reduction in the frequency of exacerbations in the pooled analysis of both replicate trials (10), but no benefit in terms of symptoms and similar results were observed in the large RESPIRE programme (9, 23). It seems therefore that for antibiotics, the benefit in exacerbation reduction is disconnected from baseline symptoms or symptom responses.

Nevertheless, the finding in recent studies that pulmonary rehabilitation and airway clearance can reduce exacerbation frequency suggests that at least a subset of exacerbations are symptom driven and therefore preventable with treatment focused on symptoms (24–26). It is tempting therefore to speculate that antibiotics prevent a subset of exacerbations that are inflammation and infection driven (27, 28), while symptomatic therapies may prevent a different exacerbation subtype. This is analogous to the established concept in COPD that bronchodilators reduce exacerbations through reducing symptoms and are therefore indicated as first line treatment for patients with symptoms and exacerbations (GOLD D) while inhaled corticosteroids appear to reduce exacerbations independent of symptom reductions and are therefore indicated both in patients with exacerbations and low symptom burden (GOLD C) and GOLD D patients that continue to exacerbate despite symptomatic therapy (16). Confirming that this concept also applies in bronchiectasis will require further experimental work including testing the role of airway inflammation as a mediator in these relationships. This concept would predict that anti-inflammatory therapies such as neutrophil elastase inhibitors may reduce exacerbations without having a large effect on symptoms.

Our results nevertheless support the “treatable traits” concept in management of bronchiectasis. In patients with frequent exacerbations with a low symptom burden, it may be adequate to treat such patients with airway clearance and the addition of anti-infective or anti-inflammatory therapy with macrolides, inhaled antibiotics or inhaled corticosteroids if they continue to frequently exacerbate. In contrast, in patients with a high symptom burden, symptomatic treatment with airway clearance and mucoactive drugs may be

effective to prevent exacerbations, contributing to antibiotic stewardship. In patient with both a high symptom burden and a high frequency of exacerbations, there is likely to be requirement for therapy directed at both aspects of disease, using phenotyping/endotyping to identify the most appropriate therapies (29, 30).

Our analysis has limitations. The observational cohort and mannitol trials were conducted prior to the validation of the quality of life bronchiectasis questionnaire and bronchiectasis health questionnaire which are specific for bronchiectasis (31–33), but we and others have demonstrated that the QOL-B and SGRQ are highly correlated and the SGRQ is the most widely used quality of life tool in bronchiectasis research and particularly in clinical trials (31, 33, 34). The analysis of the mannitol study is post-hoc and results should be considered as hypothesis generating.

In summary, we have demonstrated that patients with a high burden of symptoms are at higher risk of exacerbations even after adjustment for underlying severity of disease. This highlights the importance of therapies focused on symptom improvements and the potential need for multimodality treatment in patients with the most severe disease.

## References

1. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. The bronchiectasis severity index an international derivation and validation study. *Am J Respir Crit Care Med* 2014;189:576–585.
2. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. *Eur Respir J* 2017;49: 1700051.
3. Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ. Characterization of the “frequent exacerbator phenotype” in bronchiectasis. *Am J Respir Crit Care Med* 2018;197:1410–1420.
4. Diel R, Chalmers JD, Rabe KF, Nienhaus A, Loddenkemper R, Ringshausen FC. Economic burden of bronchiectasis in Germany. *Eur Respir J* 2019;53:1802033.
5. Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, Upton A, Wichmann K, Xu W, Chalmers JD. The economic burden of bronchiectasis – known and unknown: a systematic review. *BMC Pulm Med* 2019;19:54.

6. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J* 2017;50:1700629.
7. Hill A, Sullivan A, Chalmers J, De Soyza A, Stuart Elborn J, Andres Floto R, Grillo L, Gruffydd-Jones K, Harvey A, Haworth C, Hiscocks E, Hurst J, Johnson C, Kelleher W, Bedi P, Payne K, Saleh H, Screatton N, Smith M, Tunney M, Whitters D, Wilson R, Loebinger M. British Thoracic Society Guideline for bronchiectasis in adults. *Thorax* 2019;74:1–69.
8. Martínez-García MÁ, Máiz L, Oliveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C. Spanish Guidelines on Treatment of Bronchiectasis in Adults. *Arch Bronconeumol* 2018;54:88–98.
9. De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. *Eur Respir J* 2018;51:1702052.
10. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with *Pseudomonas aeruginosa*

- (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. *Lancet Respir Med* 2019;7:213–226.
11. Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. *Lancet Respir Med* 2019;7:855-869.
  12. Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N, Taylor SL, Martin ML, Burr LD, Wong C, Altenburg J. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. *Lancet Respir Med* 2019;7:845-854.
  13. Mackay AJ, Kostikas K, Murray L, Martinez FJ, Miravitlles M, Donaldson G, Banerji D, Patalano F, Wedzicha JA. Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. *Am J Respir Crit Care Med* 2018;198:730–738.
  14. Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D. Effects of baseline symptom burden on treatment response in COPD. *Int J Chron Obstruct Pulmon Dis* 2019;14:181–194.
  15. Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. *Chest* 2017;152:1169–1178.
  16. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin



- DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J* 2019;53:1900164.
17. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJA, O'Dochartaigh C, Van Haren EHJ, Vidal LO, Welte T, Fox HG, Wu J, Charlton B. Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial. *Thorax* 2014;69:1073–1079.
  18. WILSON CB, JONES PW, O'LEARY CJ, COLE PJ, WILSON R. Validation of the St. George's Respiratory Questionnaire in Bronchiectasis. *Am J Respir Crit Care Med* 1997;156:536–541.
  19. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012;380:660–667.
  20. Lee S Do, Huang MS, Kang J, Lin CH, Park MJ, Oh YM, Kwon N, Jones PW, Sajkov D. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. *Respir Med* 2014;108:600–608.
  21. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R,

- Rennard S, Tashkin DP, Han MK. Clinical significance of symptoms in smokers with preserved pulmonary function. *N Engl J Med* 2016;374:1811–1821.
22. Martinez CH, Murray S, Barr RG, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Krishnan JA, Lazarus SC, Leidy NK, O’Neal W, Martinez FJ, Paine R, Rennard SI, Tashkin DP, Woodruff PG, Han MK. Respiratory symptoms items from the COPD assessment test identify ever-smokers with preserved lung function at higher risk for poor respiratory outcomes an analysis of the subpopulations and intermediate outcome measures in COPD Study cohort. *Ann Am Thorac Soc* 2017;14:636–642.
  23. Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. *Eur Respir J* 2018;51:1702053.
  24. Muñoz G, de Gracia J, Buxó M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. *Eur Respir J* 2018;51:1701926.
  25. Lee AL, Hill CJ, Cecins N, Jenkins S, McDonald CF, Burge AT, Rautela L, Stirling RG, Thompson PJ, Holland AE. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis – a randomised controlled trial. *Respir Res* 2014;15:44.

26. Lee AL, Hill CJ, McDonald CF, Holland AE. Pulmonary Rehabilitation in Individuals With Non–Cystic Fibrosis Bronchiectasis: A Systematic Review. *Arch Phys Med Rehabil* 2017;98:774-782.
27. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, Elborn JS, Walker B, Martin SL, Marshall SE, Huang JT-J, Fardon TC. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. *Am J Respir Crit Care Med* 2016;195:1384–1393.
28. Gao Y, Guan W, Xu G, Lin Z, Tang Y, Lin Z, Gao Y, Li H, Zhong N, Zhang G, Chen R. The Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults: A Prospective Study. *Chest* 2015;147:1635–1643.
29. Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. *Eur Respir J* 2018;52:1801269.
30. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID. Treatable traits: toward precision medicine of chronic airway diseases. *Eur Respir J* 2016;47:410–419.
31. Spinou A, Siegert RJ, Guan W, Patel AS, Gosker HR, Lee KK, Elston C, Loebinger MR, Wilson R, Garrod R, Birring SS. The development and validation of the Bronchiectasis Health Questionnaire. *Eur Respir J* 2017;49:1601532.
32. Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of Life Questionnaire–Bronchiectasis: final psychometric analyses

- and determination of minimal important difference scores. *Thorax* 2015;70:12–20.
33. Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKeivitt M, Montgomery AB, O'Riordan TG, Barker AF. A Preliminary Quality of Life Questionnaire-Bronchiectasis: A Patient-Reported Outcome Measure for Bronchiectasis. *Chest* 2014;146:437–448.
34. Crichton ML, Aliberti S, Chalmers JD. A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults. *Eur Respir Rev* 2019;28:180108.

## Figure legends

Figure 1. Association of low (SGRQ symptom score <40 points), moderate (SGRQ symptom score 40-70 points) and high (SGRQ symptom score >70 points) symptom burden with the number of exacerbations in previous year (Panel A), Bronchiectasis Severity Index (BSI) (Panel B) and Forced expiratory volume in 1 second (Panel C). p value is from comparison of all groups (Kruskal-Wallis test for A-C)

Figure 2. Relationship between baseline SGRQ symptom score and exacerbation outcomes in the mannitol trial. The figure shows the estimated ratio between the treatment and control arms for different SGRQ scores, with 95% confidence intervals.

Figure 3. Hazard ratio for time to first exacerbation in patients with bronchiectasis divided into high, moderate and low symptom burden. The vertical dotted line represents a hazard ratio of 1.

**Table 1. Patient Demographics of All Study Population and Divided according to SGRQ symptom score in Observational Study**

	All (n=333)	Low Symptom Burden (n=82)	Moderate Symptom Burden (n=127)	High Symptom Burden (n=124)	P value
Age, yr, median (IQR)	68 (60-74)	67 (60.75-74.25)	68 (60-74)	68 (58-74)	0.76
Female sex	210 (63.1%)	54 (65.9%)	80 (63%)	76 (61.3%)	0.806
FEV1% predicted, median (IQR)	72 (50-90)	82.9 (68.0-96.9)	74.0 (59.4-91.8)	56.1 (42.2-81.9)	<0.001
BMI, kg/m <sup>2</sup> , median (IQR)	25.3 (21.8-28.6)	24.7 (21.3-27.3)	24.9 (22.0-28.4)	26.7 (22.6-30.7)	0.01
Smoking status					
Never	203 (61%)	53 (64.6%)	79 (62.2%)	71 (57.3%)	0.11
Ex-smoker	116 (34.8%)	27 (32.9%)	46 (36.2%)	43 (34.7%)	
Current	14 (4.2%)	2 (2.4%)	2 (1.6%)	10 (8.1%)	
Exacerbation in the preceding year	1 (0-3)	1 (0-2)	1.5 (0-2)	3 (1-5)	<0.001
Radiologic score, median (IQR)	3 (2-6)	3 (2-5)	3.5 (2-6)	3 (2-7)	0.24
<i>Pseudomonas aeruginosa</i>	47 (13.9%)	2 (2.4%)	16 (12.6%)	29 (23.4%)	<0.001
<i>Haemophilus influenzae</i>	109 (32.2%)	25 (30.5%)	28 (22.0%)	54 (43.5%)	0.001
<i>Moraxella catarrhalis</i>	42 (12.4%)	7 (8.5%)	11 (8.7%)	23 (18.5%)	0.03
<i>Staphylococcus aureus</i>	30 (8.8%)	4 (4.9%)	14 (11.0%)	11 (8.9%)	0.28
Enterobacteriaceae	42 (12.4%)	6 (7.3%)	19 (15.0%)	17 (13.7%)	0.24
SGRQ symptom score, median (IQR)	59.8 (40.1-79.8)	27.5 (15.2-32.7)	55.5 (48.6-61.6)	85.8 (77.8-90.6)	<0.001
LCQ total score median (IQR)	14.3 (10.6-17.9)	18.9 (16.8-20.1)	14.9 (11.9-17.6)	10.2 (7.9-13.1)	<0.001
Etiology					
Idiopathic	159 (47.7%)	48 (58.5%)	51 (40.2%)	60 (48.4%)	0.03
Post-infection	62 (18.6%)	16 (19.5%)	32 (25.2%)	14 (11.3%)	0.02
Previous ABPA	29 (8.7%)	4 (4.9%)	12 (9.4%)	13 (10.5%)	0.31
Asthma	9 (2.7%)	2 (2.4%)	3 (2.4%)	4 (3.2%)	0.90
COPD	14 (4.2%)	4 (4.9%)	5 (3.9%)	5 (4%)	0.94
Rheumatoid arthritis	13 (3.9%)	2 (2.4%)	3 (2.4%)	8 (6.5%)	0.19
Immunodeficiency	16 (4.8%)	3 (3.7%)	6 (4.7%)	7 (5.6%)	0.80
Sarcoidosis	6 (1.8%)	1 (1.2%)	3 (2.4%)	2 (1.6%)	0.82
IBD	9 (2.7%)	0 (0)	5 (3.9%)	4 (3.2%)	0.07
Comorbidities					
Cardiac disease	66 (19.8%)	16 (19.5%)	29 (22.8%)	21 (16.9%)	0.50
Stoke	31 (9.3%)	11 (13.4%)	15 (11.8%)	5 (4.0%)	0.04

Diabetes	39 (11.7%)	15 (18.3%)	6 (4.7%)	18 (14.5%)	0.006
Osteoporosis	20 (6.0%)	5 (6.1%)	6 (4.7%)	9 (7.3%)	0.70

Data were presented as mean (standard deviation, SD), median (interquartile range, IQR), number (%) as appropriate.

Abbreviation: ABPA=allergic bronchopulmonary aspergillosis; BMI=body mass index kg/m<sup>2</sup>; COPD=chronic obstructive pulmonary disease; FEV<sub>1</sub>=forced expiratory volume in 1 s; IBD=Inflammatory bowel disease; LCQ=Leicester Cough Questionnaire; SGRQ=St. George's Respiratory Questionnaire; yr=year;

**Table 2. Relationship Between Baseline SGRQ Symptom Score and Exacerbations in Observational Study**

SGRQ symptom score	Exacerbations (any)		Hospitalizations		Time to first exacerbations	
	Rate ratio (95% CI)	P value	Rate ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Uncategorized score (unadjusted)	1.15 (1.09-1.21)	<0.001	1.27 (1.15-1.39)	<0.001	1.07 (1.01-1.13)	0.02
Uncategorized score (adjusted)	1.10 (1.03-1.17)	0.005	1.19 (1.02-1.35)	0.03	1.04 (0.997-1.10)	0.27
Categorized score (unadjusted)						
Low (<40)	1		1		1	
Moderate (40-70)	1.07 (0.73-1.58)	0.72	3.53 (1.31-9.54)	0.01	0.96 (0.66-1.38)	0.3
High (>70)	2.33 (1.61-3.37)	<0.001	6.88 (2.59-17.73)	<0.001	1.41 (0.99-2.02)	0.06
Categorized score (adjusted)						
Low (<40)	1					
Moderate (40-70)	1.01 (0.66-1.54)	0.96	2.29 (0.77-6.83)	0.14	0.96 (0.65-1.43)	0.84
High (>70)	1.74 (1.12-2.72)	0.01	3.28 (1.09-9.88)	0.04	1.16 (0.76-1.77)	0.49

\*Adjusted for age, sex, BMI, smoking, FEV<sub>1</sub> % of predicted, Pseudomonas aeruginosa isolation, Haemophilus influenzae isolation, Moraxella catarrhalis isolation, idiopathic bronchiectasis, post-infective bronchiectasis, radiological score. CI=confidence interval.



**Table 3. Relationship Between Baseline SGRQ Symptom Score and Exacerbations in Mannitol Study**

SGRQ symptom score	Exacerbations		Time to first exacerbations	
	Rate ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Uncategorized score (unadjusted)	1.09 (1.02-1.16)	0.011	1.10 (1.04-1.17)	0.001
Uncategorized score (adjusted)*	1.09 (1.02-1.17)	0.017	1.09 (1.02-1.15)	0.009
Categorized score (unadjusted)				
Low (<40)	1		1	
Moderate (40-70)	1.45 (0.91-2.33)	0.12	1.74 (1.08-2.79)	0.02
High (>70)	1.71 (1.07-2.76)	0.03	1.87 (1.16-3.02 )	0.01
Categorized score (adjusted)*				
Low (<40)	1		1	
Moderate (40-70)	1.50 (0.92-2.45)	0.10	1.73 (1.07-2.80)	0.03
High (>70)	1.75 (1.07-2.86)	0.03	1.78 (1.09-2.90)	0.02

\*Adjusted for age, sex, BMI, smoking, FEV<sub>1</sub> % of predicted, *Pseudomonas aeruginosa* isolation, *Haemophilus influenzae* isolation, *Moraxella catarrhalis* isolation, idiopathic bronchiectasis, post-infective bronchiectasis, radiological score. CI=confidence interval.




Figure 1. Association of low (SGRQ symptom score<40 points), moderate (SGRQ symptom score 40-70 points) and high (SGRQ symptom score>70 points) symptom burden with the number of exacerbations in previous year (Panel A), Bronchiectasis Severity Index (BSI) (Panel B) and Forced expiratory volume in 1 second (Panel C). p value is from comparison of all groups (Kruskall-Wallis test for A-C)

312x93mm (300 x 300 DPI)




Figure 2. Relationship between baseline SGRQ symptom score and exacerbation outcomes in the mannitol trial. The figure shows the estimated ratio between the treatment and control arms for different SGRQ scores, with 95% confidence intervals.

338x169mm (300 x 300 DPI)




Figure 3. Hazard ratio for time to first exacerbation in patients with bronchiectasis divided into high, moderate and low symptom burden. The vertical dotted line represents a hazard ratio of 1.

113x90mm (300 x 300 DPI)

ONLINE SUPPLEMENT FOR

**The Relationship Between Symptoms, Exacerbations and Treatment Response in  
Bronchiectasis**

**Yong-hua Gao<sup>1,2</sup>, Hani Abo Leyah<sup>2</sup>, Simon Finch<sup>2</sup>, Mike Lonergan<sup>2</sup>, Stefano Aliberti<sup>3</sup>, Anthony  
De Soyza<sup>4</sup>, Thomas C Fardon<sup>2</sup>, Gregory Tino<sup>5</sup>, James D Chalmers<sup>2</sup>**

1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of  
Zhengzhou University, Zhengzhou, Henan, China

2Scottish Centre for Respiratory Medicine, University of Dundee, Dundee, United Kingdom

3Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

5Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

**Corresponding author:** Prof James D Chalmers, Scottish Centre for Respiratory Research,  
University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. E-mail:  
jchalmers@dundee.ac.uk

**Running head:** Symptom and exacerbation in bronchiectasis

**Subject category:** 10.16: Non-cystic fibrosis bronchiectasis

**Word count of the manuscript:** 3726

**Supported by:** This study was funded by the European Respiratory Society through the EMBARC2 consortium and an ERS long-term research Fellowship 2019 to YHG (LTRF201901-00561). JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research.

## Supplementary methods

Leicester cough questionnaire (LCQ): daily symptom burden was also measured using LCQ total score, an instrument that is validated in bronchiectasis for assessing cough (1). We divided patients with 3 groups: high symptom burden (<11), moderate symptom burden (11-17), and low symptom burden (>17). These cut-offs were determined based on tertiles (tertiles were identified based on cut-offs of 11.68 and 16.86 points. Therefore, for clinical ease, 11 and 17 were chosen as cut-offs).

## Supplementary results

### Observational study

The results of univariate and multivariate analyses evaluating the relationship between the SGRQ total score and risk of exacerbations and time to first exacerbation are summarized in Table S1. SGRQ total score was still a significant predictor of future exacerbations (RR 1.15, 95% CI 1.07-1.23,  $P<0.0001$ ) and higher SGRQ total score was associated with shorter time to first exacerbation (HR 1.11, 95% CI 1.01-1.19,  $P=0.004$ ) after adjusting the relevant confounders.

The results of univariate and multivariate analyses evaluating the relationship between the LCQ total score and risk of exacerbations and time to first exacerbation are summarized in Table S2. LCQ total score was a significant predictor of future exacerbations when entered as a continuous variable in the negative binomial model (RR 0.95, 95% CI 0.91-0.98,  $P=0.005$ ) and a trend for shorter time to first exacerbation (HR 0.97, 95% CI 0.94-1.01,  $P=0.14$ ) after adjusting the relevant confounders. Using the cutoffs, high LCQ total score <11 was associated with significantly higher exacerbation risk (RR 2.18; 95% CI 1.51-3.15;  $p<0.001$ ), and a shorter time to

first exacerbation (HR 1.45; 95% CI 1.02-2.06;  $p=0.04$ ) compared to patients with lower LCQ total score. Compared to those with low symptom scores, a moderate LCQ total score was also associated with higher exacerbation risk (RR 1.49; 95% CI 1.06-2.10;  $P=0.02$ ). The difference for time to first exacerbation was not statistically significant (HR 0.99; 95% CI 0.71-1.37;  $P=0.93$ ) in unadjusted analysis when comparing moderate and low LCQ total score categories. The higher risk in the highly symptomatic group remained significant even after adjusting the effect of potential confounders for the risk of having bronchiectasis exacerbation (RR 1.70; 95% CI 1.09-2.64;  $p=0.02$ ), but these associations were lost for time to first exacerbation (HR 1.33; 95% CI 0.89-1.99;  $P=0.17$ ).

In addition, the relationship between symptoms and exacerbation risk classified by bronchiectasis severity index (BSI) and FEV1 % of predicted as measures of disease severity, respectively, were shown in Figure S2. The RR and 95% CI for exacerbation rate was 1.10 (1.00-1.20,  $P=0.05$ ) in patients with severe bronchiectasis ( $BSI \geq 9$  points), as compared with 1.07 (0.998-1.16,  $P=0.15$ ) in patients with moderate bronchiectasis ( $BSI=5-8$  points), and 1.07 (0.994-1.02,  $P=0.30$ ) in patients with mild bronchiectasis ( $BSI=0-4$  points). And the RR and 95% CI for exacerbation rate was 1.19 (1.05-1.34,  $P=0.009$ ) in patients with FEV1 % of predicted  $<50\%$ , as compared with 1.15 (1.05-1.26,  $P=0.003$ ) in patients with FEV1 % of predicted  $\geq 50\%$ ,  $\leq 80\%$ , and 1.13 (1.04-1.22,  $P=0.005$ ) in patients with FEV1 % of predicted  $>80\%$ .

### **Mannitol study**

The relationship between symptoms and exacerbation risk classified by bronchiectasis severity index (BSI) and FEV1 % of predicted as measures of disease severity, respectively, were shown



in Figure S3. The RR and 95% CI for exacerbation rate was 1.09 (0.994-1.24,  $P=0.26$ ) in patients with severe bronchiectasis ( $BSI \geq 9$  points), as compared with 1.06 (0.996-1.15,  $P=0.26$ ) in patients with moderate bronchiectasis ( $BSI=5-8$  points), and 1.12 (0.996-1.29,  $P=0.13$ ) in patients with mild bronchiectasis ( $BSI=0-4$  points). And the RR and 95% CI for exacerbation rate was 1.15 (0.997-1.33,  $P=0.10$ ) in patients with  $FEV1$  % of predicted  $<50\%$ , as compared with 1.07 (0.999-1.16,  $P=0.09$ ) in patients with  $FEV1$  % of predicted  $\geq 50\%$ ,  $\leq 80\%$ , and 1.13 (0.991-1.37,  $P=0.25$ ) in patients with  $FEV1$  % of predicted  $>80\%$ .

The results of univariate and multivariate analyses evaluating the relationship between the SGRQ symptom score in control arm and risk of exacerbations and time to first exacerbation in control arm are summarized in Table S4. SGRQ symptom score was a significant predictor of future exacerbations (RR 1.14, 95% CI 1.03-1.25,  $P=0.01$ ) and higher symptoms were associated with shorter time to first exacerbation (HR 1.14, 95% CI 1.05-1.24,  $P=0.002$ ) after adjusting the relevant confounders. In unadjusted analysis, higher SGRQ symptom score categories were associated with a trend of higher exacerbation risk (RR 1.97; 95% CI 0.98-3.96;  $p=0.06$ ), and shorter time to first exacerbation (HR 2.21; 95% CI 1.14-4.28;  $p=0.02$ ) compared with low symptom burden. These relationships remained significant even after adjusting the effect of potential confounders for the risk of shorter time to first exacerbation compared with the low burden (HR 2.09; 95% CI 1.06-4.12;  $p=0.033$ ).

## References

1. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. *Eur Respir J* 2009; 34 (1): 125-131

## Figure Legends

Figure S1. Correlation between SGRQ symptom score and the number of exacerbations in previous year ( $\rho=0.39$ ,  $P<0.0001$ ) (Panel A), bronchiectasis severity index ( $\rho=0.39$ ,  $P<0.0001$ ) (Panel B) and FEV1 % of predicted in Observational study ( $\rho=-0.37$ ,  $P<0.0001$ ) Panel C).

Figure S2. Rate ratio for baseline SGRQ symptom score and future exacerbation risk in patients with different disease severity assessed by bronchiectasis severity index (Panel A) and FEV1 % of predicted (Panel B) in Observational study. Error bars represent 95% CI. The vertical dotted line represents a rate ratio of 1.

Figure S3. Rate ratio for baseline SGRQ symptom score and future exacerbation risk in patients with different disease severity assessed by bronchiectasis severity index (Panel A) and FEV1 % of predicted (Panel B) in Mannitol study. Error bars represent 95% CI. The vertical dotted line represents a rate ratio of 1.

Figure S4. Kaplan-Meier plot of the time to first exacerbation in high symptomatic patients.

**Table S1. Relationship Between Baseline SGRQ Total Score and Exacerbations in Observational Study**

SGRQ total score	Exacerbations			Time to first exacerbations		
	Rate ratio	(95% CI)	p value	Hazard ratio CI)	(95%	p value
Uncategorized score (unadjusted)	1.16	(1.11-1.22)	<0.0001	1.13	(1.06-1.19)	<0.0001
Uncategorized score (adjusted)*	1.15	(1.07-1.22)	<0.0001	1.11	(1.04-1.19)	0.004

\*Adjust for age, gender, BMI, FEV<sub>1</sub> % of predicted, smoking status, Pseudomonas aeruginosa isolation, Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic bronchiectasis, post-infective bronchiectasis

**Table S2. Relationship Between Baseline LCQ Total Score and Exacerbations in Observational Study**

LCQ total score	Exacerbations			Time to first exacerbations		
	Rate ratio	(95% CI)	p value	Hazard ratio	(95% CI)	p value
Uncategorized score (unadjusted)	0.93	(0.90-0.95)	<0.001	0.97	(0.94-1.00)	0.02
Uncategorized score (adjusted)*	0.95	(0.91-0.98)	0.005	0.97	(0.94-1.01)	0.14
Categorized score (unadjusted)						
Low (>17)	1					
Moderate (11-17)	1.49	(1.06-2.10)	0.02	0.99	(0.71-1.37)	0.93
High (<11)	2.18	(1.51-3.15)	<0.001	1.45	(1.02-2.06)	0.04
Categorized score (adjusted)*						
Low (>17)	1					
Moderate (11-17)	1.48	(1.02-2.16)	0.04	1.03	(0.72-1.47)	0.88
High (<11)	1.70	(1.09-2.64)	0.02	1.33	(0.89-1.99)	0.17

\*Adjust for age, gender, BMI, FEV<sub>1</sub> % of predicted, smoking status, Pseudomonas aeruginosa isolation, Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic bronchiectasis, post-infective bronchiectasis

**Table S3. Patient Demographics of All Study Population and Divided according to SGRQ Symptom Score in Mannitol Study**


	All (n=461)	Low Symptom Burden (n=35)	Moderate Symptom Burden (n=232)	High Symptom Burden (n=194)	P value
Age, yr, median (IQR)	63 (53-69)	68 (57-70)	62 (50.3-69)	63 (55.8-69)	0.24
Female sex	289 (62.7%)	23 (65.7%)	149 (64.2%)	117 (60.3%)	0.66
FEV <sub>1</sub> % predicted, median (IQR)	61.9 (51.9-72.3)	67.3 (59.0-76.0)	61.1 (50.3-71.5)	61.6 (51.8-72.5)	0.12
BMI, kg/m <sup>2</sup> , median (IQR)	25.6 (22.4-29.1)	26.2 (21.6-28.7)	25.1 (21.8-28.3)	26.4 (22.8-29.7)	0.04
Ex-smoker	181 (39.3%)	12 (34.3%)	82 (35.3%)	87 (44.8%)	0.11
Exacerbation in the preceding year	3 (2-4)	2 (2-4)	3 (2-4)	3 (2-4)	0.14
Pseudomonas aeruginosa	79 (17.1%)	2 (5.7%)	41 (17.7%)	36 (18.6%)	0.11
Haemophilus influenzae	67 (14.5%)	7 (20%)	30 (12.9%)	30 (15.5%)	0.48
Moraxella catarrhalis	16 (3.5%)	3 (8.6%)	6 (2.6%)	7 (3.6%)	0.28
Staphylococcus aureus	13 (2.8%)	2 (5.7%)	6 (2.6%)	5 (2.6%)	0.63
Streptococcus pneumoniae	20 (4.3%)	2 (5.7%)	10 (4.3%)	8 (4.1%)	0.92
SGRQ symptom score, median (IQR)	66.1 (53.9-77.7)	32.4 (27.2-37.8)	57.7 (50.7-64.5)	79.4 (75.2-85.0)	<0.001
Etiology					
Idiopathic	179 (38.8%)	14 (40.0%)	99 (42.7%)	66 (34.0%)	0.19
Post-infection	152 (33.0%)	15 (42.9%)	81 (34.9%)	56 (28.9%)	0.18

Data were presented as mean (standard deviation, SD), median (interquartile range, IQR), number (%) as appropriate. Abbreviation: BMI=body mass index kg/m<sup>2</sup>; FEV<sub>1</sub>=forced expiratory volume in 1 s; SGRQ=St. George's Respiratory Questionnaire; yr=year;

**Table S4. Relationship between baseline SGRQ symptom score and exacerbations in control arm in Mannitol study**

SGRQ symptom score	Exacerbations			Time to first exacerbations		
	Rate ratio	(95% CI)	p value	Hazard ratio CI)	(95% CI)	p value
Uncategorized score (unadjusted)	1.15	(1.05-1.26)	0.004	1.17	(1.08-1.26)	<0.001
Uncategorized score (adjusted)*	1.14	(1.03-1.25)	0.01	1.14	(1.05-1.24)	0.002
Categorized score (unadjusted)						
Low (<40)	1					
Moderate (40-70)	1.41	(0.71-2.84)	0.33	1.54	(0.80-2.97)	0.20
High (>70)	1.97	(0.98-3.96)	0.06	2.21	(1.14-4.28)	0.02
Categorized score (adjusted)*						
Low (<40)	1			1		
Moderate (40-70)	1.41	(0.69-2.90)	0.34	1.54	(0.79-3.02)	0.21
High (>70)	1.91	(0.93-3.95)	0.08	2.09	(1.06-4.12)	0.03


\*Adjust for age, gender, BMI, FEV<sub>1</sub> % of predicted, smoking status, Pseudomonas aeruginosa isolation, Haemophilus influenzae isolation, Moraxella catarrhalis isolation, radiological score, idiopathic bronchiectasis, post-infective bronchiectasis



Supplementary Figure 1


297x74mm (300 x 300 DPI)






Supplementary Figure 2

231x93mm (300 x 300 DPI)



Supplementary Figure 3

237x93mm (300 x 300 DPI)



**Patients with high SGRQ symptom score**

Supplementary Figure 4

148x112mm (300 x 300 DPI)